The inventor and developer of a drug, nusinersen (Spinraza), are among the winners of the Breakthrough Prize in Life Sciences. Adrian Krainer (pictured) of Cold Spring Harbor Laboratory and Frank Bennett, senior vice president of research at Ionis Pharmaceuticals, share the... Read more »
Security-tech company Cybereason is announcing another boon flowing from close ties with its biggest investor, Japanese telecom and tech giant SoftBank. Boston-based Cybereason has formed a partnership with Arm, the dominant developer of computer chip architecture, which was acquired by SoftBank in... Read more »
Origin Code Academy, one of San Diego’s few coding schools—for-profit companies that offer short-term vocational training in computer programming—said this month it will shutter on Nov. 16 after about three years in business.
The company opened in late 2015, offering a... Read more »
Technology and life sciences leaders say they’ll remember Paul Allen, the Microsoft co-founder, philanthropist, and investor who passed away Monday at age 65, as an “inspiration” whose work will impact the fields he worked in for years to come.
Allen died... Read more »
Tulerie makes its debut today, joining a growing roster of online clothing rental startups.
The New York-based Tulerie focuses on high-end couture—items that retail for $1,000 to $10,000—that might be worn a time or two but mostly take up space in... Read more »
Blockchain and cryptocurrency advocates have been waiting for large financial institutions to shed their wariness and begin investing meaningful amounts of money into the emerging technology. The sector may have gotten a significant catalyst on Monday, when Fidelity Investments announced it... Read more »
More days than not, Michael Colaneri’s home is a hotel room. So innovations like “geolocation” sensors that automatically unlock his room door and adjust the thermostat when he’s nearby make the constant change easier—sometimes.
“My experience has been exceptionally inconsistent,” he... Read more »
MIT is making another significant investment in artificial intelligence. The Institute announced Monday that it will establish a new college on its Cambridge, MA, campus—the MIT Stephen A. Schwarzman College of Computing—that will serve as an interdisciplinary hub for advancing ideas... Read more »
Nivolumab (Opdivo) recently became the first immunotherapy ever approved for people with small cell lung cancer (SCLC), a particularly aggressive form of the deadly disease. But the lead given to its developer, Bristol-Myers Squibb, may be short-lived.
Bristol (NYSE: BMY)... Read more »
The number of biotech companies completing an IPO has swelled this year and Adynxx aims to join their ranks—but through an alternate path. The pain drug developer has agreed to combine operations with publicly traded Alliqua Biomedical.
Under the merger agreement... Read more »
Nearly four years after investors snapped up new shares of Juno Therapeutics in a $265 million IPO, cancer immunotherapy remains a hot ticket. Like Juno, Allogene Therapeutics just pulled in a massive IPO haul, nearly $300 million. And like Juno, Allogene... Read more »
In another wave of account shutdowns, Facebook announced Thursday that it disabled more than 800 pages and accounts to prevent groups that disguised their identities from flooding its network with inauthentic content—some of it hyper-partisan political messages.
Facebook (NASDAQ: FB)... Read more »
Whether from embarrassing parties or sobering surveys, the biotech gender gap problem has made plenty of headlines the past couple years. The industry’s largest trade group, the Biotechnology Industry Organization (BIO), is trying to encourage its more than 1,000 member companies... Read more »